Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 196,616 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALL Clear all
Completed Phase 2 Interventional

A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

NCT00952497
View directory record Official record
Conditions
Gastric Cancer
Interventions
Cisplatin, Capecitabine, Telatinib
Drug
Lead sponsor
ACT Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
San Francisco, California • Macon, Georgia • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational Results available

Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology

NCT02123797
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Baptist Memorial Health Care Corporation
Other
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational

Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension

NCT01862497
View directory record Official record
Conditions
Intradialytic Hypertension
Interventions
Carvedilol vs. Prazosin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing the Efficacy of Smoking Quit Line in the Military (AFIII Renewal)

NCT02201810
View directory record Official record
Conditions
Initial Efficacy of Quit Line, Efficacy of Secondary Reengagement Intervention
Interventions
Rate reduction intervention, Recycling Group, Choice Group, Proactive QL
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

NCT05421013
View directory record Official record
Conditions
Facial isSCC
Interventions
STP705
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 3 Interventional

Enhancing Communication and HIV Outcomes

NCT00675610
View directory record Official record
Conditions
HIV Infections
Interventions
communication training
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 2 Interventional

Photosensitivity Proof of Concept Trial

NCT00894010
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
carbamazepine 400mg, levetiracetam 1000mg
Drug
Lead sponsor
The Epilepsy Study Consortium
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional

Compass 3: A Novel Transition Program to Reduce Disability After Stroke

NCT07069660
View directory record Official record
Conditions
Stroke
Interventions
COMPASS, Education Program
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Columbia, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Teachers and Parents as Partners During Middle School RCT

NCT03614026
View directory record Official record
Conditions
Behavior Disorders
Interventions
Teachers and Parents as Partners
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer

NCT03125226
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Polyethylene Glycol Hydrogel
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated No phase listed Observational

Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

NCT01319526
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
DNA analysis, RNA analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Severe Asthma Research Program

NCT01606826
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years and older
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107926
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
La Palma, California • Kansas City, Kansas • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycine vs Placebo for the Schizophrenia Prodrome

NCT00291226
View directory record Official record
Conditions
Schizophrenia Prodrome
Interventions
Glycine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer

NCT00735878
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
ABT-751 and Carboplatin
Drug
Lead sponsor
Konstantin Dragnev
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1
Drug
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

NCT00352885
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo, IL-2
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational

Transcranial Direct Current Stimulation to Improve Hand Movement in Stroke Patients

NCT00307385
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

NCT01982643
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
naltrexone plus bupropion
Drug
Lead sponsor
Walter Ling
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Not applicable Interventional Results available

Optical Imaging of Head and Neck Cancer

NCT01456143
View directory record Official record
Conditions
Squamous Cell Carcinoma, Neoplasia, Head and Neck Cancer
Interventions
High Resolution Microendoscopy (HRME), Proflavine hemisulfate
Device · Other
Lead sponsor
Sharmila Anandasabapathy, MD
Individual
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engineering an Online STI Prevention Program: CSE2

NCT03408743
View directory record Official record
Conditions
Alcohol Consumption, Sexually Transmitted Diseases
Interventions
Knowledge Alone, Self-efficacy alone, Perceived benefits alone, Benefits and self-efficacy, Injunctive norms alone, Injunctive norms and self-efficacy, Injunctive norms and benefits, Injunctive norms, benefits, self-efficacy, Descriptive norms alone, Descriptive norms and self-efficacy, Descriptive norms and perceived benefits, Descriptive norms, benefits, self-efficacy, Descriptive norms and injunctive norms, Descriptive and injunctive norms, self-efficacy, Descriptive and injunctive norms, and benefits, Descriptive & injunctive norms, benefits, efficacy, Expectancies alone, Expectancies and self-efficacy, Expectancies and perceived benefits, Expectancies, benefits, self-efficacy, Expectancies and injunctive norms, Expectancies, injunctive norms, self-efficacy, Expectancies, injunctive norms, and benefits, Expectancies, injunctive norms, benefits, efficacy, Expectancies and descriptive norms, Expectancies, descriptive norms, & self-efficacy, Expectancies, descriptive norms, benefits, Expectancies, descriptive norms, benefits, efficacy, Expectancies, descriptive and injunctive norms, Expectancies, descriptive & injunctive norms, efficacy, Expectancies, descriptive & injunctive norms, benefits, Expectancies, descriptive & injunctive, benefits, efficacy
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years
Enrollment
2,946 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
4
States / cities
Fresno, California • Fargo, North Dakota • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

NCT01301443
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Subretinally injected RetinoStat
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 30, 2026, 8:23 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

NCT02929485
View directory record Official record
Conditions
Addiction
Interventions
Tolcapone, Placebo, Bromocriptine
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational Results available

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

NCT00823043
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
timolol hemihydrate, timolol maleate
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 30, 2026, 8:23 PM EDT